Cart
sales@molnova.com
Androstane-3,6,17-triol
CAS No. 49644-04-4
Androstane-3,6,17-triol( —— )
Catalog No. M37490 CAS No. 49644-04-4
Androstane-3,6,17-triol is a trihydroxy compound present in mouse prostate microsomes and is a testosterone metabolite.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | 92 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameAndrostane-3,6,17-triol
-
NoteResearch use only, not for human use.
-
Brief DescriptionAndrostane-3,6,17-triol is a trihydroxy compound present in mouse prostate microsomes and is a testosterone metabolite.
-
DescriptionAndrostane-3,6,17-triol is a trihydroxy compound present in mouse prostate microsomes and is a testosterone metabolite.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number49644-04-4
-
Formula Weight308.46
-
Molecular FormulaC19H32O3
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C[C@H](O)[C@@]2([H])C[C@@H](O)CC[C@]12C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
PBIT
PBIT inhibits JARID1B histone demethylase (IC50 of about 3 μM). PBIT also inhibits JARID1A and JARID1C (IC50s of 6 μM and 4.9 μM, respectively). PBIT is a specific inhibitor of the Jumonji AT-rich Interactive Domain 1 (JARID1) enzymes . PBIT, which inhibits JARID1B with an IC50 of about 3 μm in vitro.
-
cis-Tiliroside
Kaempferol-3-O-α2-D-(6''-O-coumaryl) glycoside has antioxidant activity and α±-glucosidase inhibitory effects, it could potentially be used for food additives and the development of useful natural compounds.
-
Cergutuzumab amunale...
Cergutuzumab amunaleukin (CEA-IL2v) is a CEA-targeted IL-2 variant immunocytokine for combination cancer immunotherapy with immunostimulatory and anti-tumor activities for the study of solid cancers.
